One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Pharmacological treatment for transforming growth factor beta induced corneal dystrophies: what is the way forward?
Gabriella Guo Sciriha, Janet Sultana & Joseph Borg
doi : 10.1080/17512433.2023.2193683
Expert Review of Clinical Pharmacology, Volume 16, Issue 4 (2023)
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review
Aishwarya Muddebihal, Ananta Khurana & Kabir Sardana
doi : 10.1080/17512433.2023.2193682
Numerous cutaneous dermatoses mediated by cytokines depend on the JAK STAT pathway for intracellular signaling. JAK inhibitors form a useful therapeutic approach in treating these conditions.
Pharmacological approaches to treat intestinal pain
Mikolaj Swierczynski, Adam Makaro, Agata Grochowska & Maciej Salaga
doi : 10.1080/17512433.2023.2195626
Pain is one of the most substantial factors responsible for lowering quality of life in patients with intestinal diseases. Its multifactorial pathogenesis makes intestinal pain difficult to manage with currently available medications, especially considering the risk of serious adverse effects and exacerbation of underlying disease.
Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events
Claudia St?llberger, Birke Schneider & Josef Finsterer
doi : 10.1080/17512433.2023.2187376
In randomized trials, direct oral anticoagulants (DOAC) were non-inferior to the vitamin-K-antagonist (VKA) warfarin in preventing stroke/embolism in patients with atrial fibrillation (AF). DOAC are substrates for P-glycoprotein (P-gp), CYP3A4 and CYP2C9. The activity of these enzymes is modulated by several drugs which might induce pharmacokinetic drug-drug interactions (DDI). Drugs affecting platelet function have the potential for pharmacodynamic DDI of DOAC.
Sex and gender differences in the treatment of arterial hypertension
Juan Tamargo, Ricardo Caballero & Eva Delp?n Mosquera
doi : 10.1080/17512433.2023.2189585
Arterial hypertension represents the leading modifiable risk factor for all-cause death and early development of cardiovascular disease in women. Current clinical guidelines for the treatment of hypertension noted that women respond to antihypertensive drugs similarly to men and, therefore, treatment recommendations remain the same for both sexes.
Clinical pharmacological innovation in the treatment of depression
Jeffrey M Witkin, Lalit K Golani & Jodi L Smith
doi : 10.1080/17512433.2023.2198703
Deficiencies in standard of care antidepressants are driving novel drug discovery. A new age of antidepressant medications has emerged with the introduction of rapid-acting antidepressants with efficacy in treatment-resistant patients.
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial
Zhongnan Xu, Zhengzhi Liu, Yanli Wang, Jinling Xue, Tianying Chang, Yingzi Cui, Yang Cheng, Guangwen Liu, Wanhua Wang, Yannan Zhou, Shuang Yu, Qing Ren, Wei Yang, Xinyao Qu, Jiahui Chen, Xuesong Chen, Qiaohuan Deng, Haimiao Yang & Xiuge Wang
doi : 10.1080/17512433.2023.2188192
Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone. Liraglutide, a GLP-1 receptor agonist, can lower blood sugar by increasing insulin production and inhibiting the production of glucagon. This study researched the bioequivalence and safety of the test and reference drugs in healthy Chinese subjects.
Germline genetic variations in methotrexate pathway are associated with pharmacokinetics, outcome, and toxicity in patients with primary central nervous system lymphoma
Zhuo Wu, Ziran Li, Xiaoyan Qiu, Mingkang Zhong & Tianling Ding
doi : 10.1080/17512433.2023.2194630
High-dose methotrexate (HD-MTX)–based regimens are the standard treatment for patients with primary central nervous system lymphoma (PCNSL); however, MTX has extensive interpatient variability in pharmacokinetics and clinical outcomes, with genetic variation an important factor involved in the variability in drug response.
